search
Back to results

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

Primary Purpose

Non Small Cell Lung Cancer, Cervical Cancer, SCCHN

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
XB002
Nivolumab
Bevacizumab
Sponsored by
Exelixis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non Small Cell Lung Cancer focused on measuring ADC, Antibody drug conjugate, Tissue Factor, Auristatin, Nivolumab, Bevacizumab

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent.
  • Dose-Escalation Stage Cohort A and AN and Cohort-Expansion Stage (Cohorts B - K, BN, FN and HN): The subject has received standard life-prolonging therapies unless they do not exist, or available therapies are intolerable or no longer effective.
  • Cohort-Expansion Stage Cohort B and BN (Non-small Cell Lung Cancer): Subjects with Stage IV NSCLC who have documented radiographic disease progression during or following their last systemic anticancer therapy.
  • Cohort-Expansion Stage Cohort C (Urothelial Cancer): Subjects with transitional cell histology (including renal pelvis, ureter, urinary bladder, urethra) who have documented radiographic disease progression during or following their last systemic anticancer therapy.
  • Cohort-Expansion Stage Cohort D (Ovarian Cancer): Subjects with high-grade serous ovarian cancer, including primary peritoneal cancer (PPC) and fallopian tube cancer (FTC) who have platinum-resistant disease following treatment with platinum-containing chemotherapy.
  • Cohort-Expansion Stage Cohort E (Cervical Cancer): Subjects with persistent, recurrent, or metastatic carcinoma of the uterine cervix who have documented radiographic disease progression during or following their last systemic anticancer therapy.
  • Cohort F and FN (SCCHN): Subjects with head and neck cancer (squamous cell histology) who have documented radiographic disease progression during or following their last systemic anticancer therapy. Allowed primary tumor locations are oral cavity, oropharynx, hypopharynx, glottic larynx. Note: Excluded are subjects with primary tumor site of the nasopharynx.
  • Cohort G (Pancreatic Cancer): Subjects with pancreatic cancer (adenocarcinoma histology) who have documented radiographic disease progression during or following their last systemic anticancer therapy.
  • Cohort H and HN (Esophageal SCC): Subjects with esophageal cancer (squamous cell histology) who have documented radiographic disease progression during or following their last systemic anticancer therapy. Note: subjects with esophageal adenocarcinoma and adenocarcinoma of gastroesophageal junction (GEJ) are excluded.
  • Cohort I (mCRPC): Subjects with metastatic, castration resistant adenocarcinoma of the prostate. Note: Neuroendocrine differentiation and other histological features are permitted if adenocarcinoma is the primary histology.
  • Cohort J (TNBC): Subjects with triple-negative (estrogen receptor negative [ER-]/progesterone receptor negative [PR-]/ human epidermal growth factor receptor 2 negative [HER-2-]) breast cancer who have documented radiographic disease progression during or following their last systemic anticancer therapy for inoperable locally advanced or metastatic disease.
  • Cohort K (HR + BC): Subjects with breast cancer that is hormone receptor-positive (ER+ and/or PR+) and HER-2-) and who have documented radiographic disease progression during or following their last systemic anticancer therapy for inoperable locally advanced or metastatic disease.
  • Expansion Cohorts: Subjects must have measurable disease per RECIST 1.1 as determined by the Investigator.
  • Tumor tissue material collected approximately 2 years prior to consent. If archival tumor tissue is not available, a fresh tumor biopsy may be collected from subjects enrolled in the Dose-Escalation Stage and must be collected from subjects in the Cohort-Expansion Stage, at least 7 days (and up to 60 days) prior to first dose.
  • Recovery to baseline or ≤ Grade 1 severity (Common Terminology Criteria for Adverse Events version 5 [CTCAE v5]) from AEs.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.
  • Adequate organ and marrow function.
  • Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception.
  • Female subjects of childbearing potential must not be pregnant at screening.

Exclusion Criteria:

  • Receipt of prior therapies as defined in study protocol
  • Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment.
  • Uncontrolled, significant intercurrent or recent illness.
  • Major surgery within 4 weeks before first dose of study treatment
  • Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms per electrocardiogram (ECG).
  • Pregnant or lactating females
  • Previously identified allergy or hypersensitivity to components of study treatment formulations or history of severe infusion-related reactions to monoclonal antibodies.
  • Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy.

Sites / Locations

  • Exelixis Clinical Site #20Recruiting
  • Exelixis Clinical Site #21Recruiting
  • Exelixis Clinical Site #16Recruiting
  • Exelixis Clinical Site #22Recruiting
  • Exelixis Clinical Site #6Recruiting
  • Exelixis Clinical Site #18Recruiting
  • Exelixis Clinical Site #25Recruiting
  • Exelixis Clinical Site #19Recruiting
  • Exelixis Clinical Site #10Recruiting
  • Exelixis Clinical Site #5Recruiting
  • Exelixis Clinical Site #11Recruiting
  • Exelixis Clinical Site #8Recruiting
  • Exelixis Clinical Site #7Recruiting
  • Exelixis Clinical Site #23Recruiting
  • Exelixis Clinical Site #12Recruiting
  • Exelixis Clinical Site #15Recruiting
  • Exelixis Clinical Site #4Recruiting
  • Exelixis Clinical Site #3Recruiting
  • Exelixis Clinical Site #24Recruiting
  • Exelixis Clinical Site #1Recruiting
  • Exelixis Clinical Site #14Recruiting
  • Exelixis Clinical Site #2Recruiting
  • Exelixis Clinical Site #9Recruiting
  • Exelixis Clinical Site #17Recruiting
  • Exelixis Clinical Site #13Recruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

XB002 Single-Agent Dose-Escalation Cohorts

XB002 Single-Agent Expansion Cohorts

XB002 + Nivolumab Dose Escalation Cohorts

XB002 + Nivolumab Dose Expansion Cohorts

XB002 + Bevacizumab Dose Escalation Cohorts

XB002 + Bevacizumab Dose Expansion Cohorts

Arm Description

Subjects (Cohort A) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.

The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with non-small cell lung cancer [NSCLC] (Cohort B), ovarian cancer (Cohort D), cervical cancer (Cohort E), SCCHN (Cohort F), pancreatic cancer (Cohort G), Esophageal SCC (Cohort H), metastatic castration-resistant prostate cancer (Cohort I), triple-negative breast cancer (Cohort J), hormone-receptor positive breast cancer (Cohort K), endometrial cancer (Cohort L) and tumor agnostic tissue factor-expressing solid tumors (Cohort M).

Subjects (Cohort AN) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.

The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with non-small cell lung cancer [NSCLC] (Cohort BN), SCCHN (Cohort FN), Esophageal SCC (Cohort HN).

Subjects (Cohort AB) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.

The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with epithelial ovarian cancer [EOC] (Cohort DB)

Outcomes

Primary Outcome Measures

Dose-Escalation Stage: MTD/recommended dose for XB002
To determine the MTD and/or RD for further evaluation of IV administration of XB002 in subjects with advanced malignancies
Cohort-Expansion Stage: Objective Response Rate (ORR)
To evaluate preliminary efficacy of XB002 by estimating the ORR per RECIST 1.1 as assessed by the Investigator

Secondary Outcome Measures

Safety of XB002: Adverse Events
To evaluate the safety of XB002 through the evaluation of incidence and severity of nonserious adverse events (AEs) and serious adverse events (SAEs)
Tolerability of XB002 as evaluated by the duration of exposure for the study
To evaluate the tolerability of XB002 through the evaluation of duration of exposure for the study treatment
Tolerability of XB002 as evaluated dose intensity of the study treatment
To evaluate the tolerability of XB002 through the evaluation of dose intensity of the study treatment
Maximum Plasma Concentration (Cmax)
To evaluate the Cmax for XB002, total antibody, and free payload at scheduled visits over time
Trough Concentration (Ctrough)
To evaluate the Ctrough of XB002, total antibody, and free payload at scheduled visits over time
Immunogenicity of XB002
To assess the immunogenicity of XB002 as measured by anti-drug antibody (ADA) analysis
Dose-Escalation Stage: Anti-tumor activity of XB002: Objective Response Rate (ORR)
To evaluate the anti-tumor activity of XB002, as measured by ORR, per RECIST 1.1 as assessed by the Investigator
Anti-tumor activity of XB002: Duration of Response (DOR)
To evaluate the anti-tumor activity of XB002, as measured by DOR, per RECIST 1.1 as assessed by the Investigator (dose escalation stage) or by a BIRC for selected cohorts (cohort expansion stage)
Anti-tumor activity of XB002: Progression Free Survival (PFS)
To evaluate the anti-tumor activity of XB002, as measured by PFS, per RECIST 1.1 as assessed by the Investigator (dose escalation stage) or by a BIRC for selected cohorts (cohort expansion stage)
Cohort-Expansion Stage: overall survival
To evaluate overall survival

Full Information

First Posted
May 27, 2021
Last Updated
September 25, 2023
Sponsor
Exelixis
search

1. Study Identification

Unique Protocol Identification Number
NCT04925284
Brief Title
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
Official Title
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 7, 2021 (Actual)
Primary Completion Date
June 7, 2024 (Anticipated)
Study Completion Date
October 7, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Exelixis

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a Phase 1, open-label, multicenter, dose-escalation and expansion study evaluating the safety, tolerability, PK, pharmacodynamics, and clinical antitumor activity of XB002 administered IV q3w alone and in combination with nivolumab or bevacizumab to subjects with advanced solid tumors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
Keywords
ADC, Antibody drug conjugate, Tissue Factor, Auristatin, Nivolumab, Bevacizumab

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Model Description
Dose-escalation followed by cohort-expansion in tumor-specific expansion cohorts
Masking
None (Open Label)
Allocation
Randomized
Enrollment
561 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
XB002 Single-Agent Dose-Escalation Cohorts
Arm Type
Experimental
Arm Description
Subjects (Cohort A) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
Arm Title
XB002 Single-Agent Expansion Cohorts
Arm Type
Experimental
Arm Description
The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with non-small cell lung cancer [NSCLC] (Cohort B), ovarian cancer (Cohort D), cervical cancer (Cohort E), SCCHN (Cohort F), pancreatic cancer (Cohort G), Esophageal SCC (Cohort H), metastatic castration-resistant prostate cancer (Cohort I), triple-negative breast cancer (Cohort J), hormone-receptor positive breast cancer (Cohort K), endometrial cancer (Cohort L) and tumor agnostic tissue factor-expressing solid tumors (Cohort M).
Arm Title
XB002 + Nivolumab Dose Escalation Cohorts
Arm Type
Experimental
Arm Description
Subjects (Cohort AN) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
Arm Title
XB002 + Nivolumab Dose Expansion Cohorts
Arm Type
Experimental
Arm Description
The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with non-small cell lung cancer [NSCLC] (Cohort BN), SCCHN (Cohort FN), Esophageal SCC (Cohort HN).
Arm Title
XB002 + Bevacizumab Dose Escalation Cohorts
Arm Type
Experimental
Arm Description
Subjects (Cohort AB) will accrue in cohorts of 3-12 subjects in a modified i3+3 design.
Arm Title
XB002 + Bevacizumab Dose Expansion Cohorts
Arm Type
Experimental
Arm Description
The MTD or recommended dose from the dose-escalation stage may be further explored in subjects with epithelial ovarian cancer [EOC] (Cohort DB)
Intervention Type
Drug
Intervention Name(s)
XB002
Intervention Description
IV administration of XB002
Intervention Type
Drug
Intervention Name(s)
Nivolumab
Intervention Description
IV administration of Nivolumab
Intervention Type
Drug
Intervention Name(s)
Bevacizumab
Intervention Description
IV administration of bevacizumab
Primary Outcome Measure Information:
Title
Dose-Escalation Stage: MTD/recommended dose for XB002
Description
To determine the MTD and/or RD for further evaluation of IV administration of XB002 in subjects with advanced malignancies
Time Frame
18 months
Title
Cohort-Expansion Stage: Objective Response Rate (ORR)
Description
To evaluate preliminary efficacy of XB002 by estimating the ORR per RECIST 1.1 as assessed by the Investigator
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Safety of XB002: Adverse Events
Description
To evaluate the safety of XB002 through the evaluation of incidence and severity of nonserious adverse events (AEs) and serious adverse events (SAEs)
Time Frame
30 months
Title
Tolerability of XB002 as evaluated by the duration of exposure for the study
Description
To evaluate the tolerability of XB002 through the evaluation of duration of exposure for the study treatment
Time Frame
30 months
Title
Tolerability of XB002 as evaluated dose intensity of the study treatment
Description
To evaluate the tolerability of XB002 through the evaluation of dose intensity of the study treatment
Time Frame
30 months
Title
Maximum Plasma Concentration (Cmax)
Description
To evaluate the Cmax for XB002, total antibody, and free payload at scheduled visits over time
Time Frame
30 months
Title
Trough Concentration (Ctrough)
Description
To evaluate the Ctrough of XB002, total antibody, and free payload at scheduled visits over time
Time Frame
30 months
Title
Immunogenicity of XB002
Description
To assess the immunogenicity of XB002 as measured by anti-drug antibody (ADA) analysis
Time Frame
30 months
Title
Dose-Escalation Stage: Anti-tumor activity of XB002: Objective Response Rate (ORR)
Description
To evaluate the anti-tumor activity of XB002, as measured by ORR, per RECIST 1.1 as assessed by the Investigator
Time Frame
30 months
Title
Anti-tumor activity of XB002: Duration of Response (DOR)
Description
To evaluate the anti-tumor activity of XB002, as measured by DOR, per RECIST 1.1 as assessed by the Investigator (dose escalation stage) or by a BIRC for selected cohorts (cohort expansion stage)
Time Frame
30 months
Title
Anti-tumor activity of XB002: Progression Free Survival (PFS)
Description
To evaluate the anti-tumor activity of XB002, as measured by PFS, per RECIST 1.1 as assessed by the Investigator (dose escalation stage) or by a BIRC for selected cohorts (cohort expansion stage)
Time Frame
30 months
Title
Cohort-Expansion Stage: overall survival
Description
To evaluate overall survival
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent. Dose-Escalation Stage Cohorts A, AB and AN and Cohort-Expansion Stage (Cohorts B - M, BN, DB, FN and HN): The subject has received standard life-prolonging therapies unless they do not exist, or available therapies are intolerable or no longer effective. Cohort-Expansion Stage Cohort B and BN (Non-small Cell Lung Cancer): Subjects with Stage IV NSCLC who have documented radiographic disease progression during or following their last systemic anticancer therapy. Cohort-Expansion Stage Cohorts D and DB (Epithelial Ovarian Cancer): Subjects with high-grade serous ovarian cancer, including primary peritoneal cancer (PPC) and fallopian tube cancer (FTC) who have platinum-resistant disease following treatment with platinum-containing chemotherapy. Cohort-Expansion Stage Cohort E (Cervical Cancer): Subjects with persistent, recurrent, or metastatic carcinoma of the uterine cervix who have documented radiographic disease progression during or following their last systemic anticancer therapy. Cohorts F and FN (SCCHN): Subjects with head and neck cancer (squamous cell histology) who have documented radiographic disease progression during or following their last systemic anticancer therapy. Allowed primary tumor locations are oral cavity, oropharynx, hypopharynx, glottic larynx. Note: Excluded are subjects with primary tumor site of the nasopharynx. Cohort G (Pancreatic Cancer): Subjects with pancreatic cancer (adenocarcinoma histology) who have documented radiographic disease progression during or following their last systemic anticancer therapy. Cohorts H and HN (Esophageal SCC): Subjects with esophageal cancer (squamous cell histology) who have documented radiographic disease progression during or following their last systemic anticancer therapy. Note: subjects with esophageal adenocarcinoma and adenocarcinoma of gastroesophageal junction (GEJ) are excluded. Cohort I (mCRPC): Subjects with metastatic, castration resistant adenocarcinoma of the prostate. Note: Neuroendocrine differentiation and other histological features are permitted if adenocarcinoma is the primary histology. Cohort J (TNBC): Subjects with triple-negative (estrogen receptor negative [ER-]/progesterone receptor negative [PR-]/ human epidermal growth factor receptor 2 negative [HER-2-]) breast cancer who have documented radiographic disease progression during or following their last systemic anticancer therapy for inoperable locally advanced or metastatic disease. Cohort K (HR + BC): Subjects with breast cancer that is hormone receptor-positive (ER+ and/or PR+) and HER-2-) and who have documented radiographic disease progression during or following their last systemic anticancer therapy for inoperable locally advanced or metastatic disease. Cohort L (Endometrial Cancer): Subjects with advanced, recurrent or metastatic endometrial cancer who have documented radiographic disease progression during or following their last systemic anticancer therapy. Cohort M (Tumor-Agnostic Tissue Factor-Expressing Solid Tumors): Subjects with solid tumors other than those designated in Cohorts B-L and those which express tissue factor. Participation in this cohort will be at selected sites and countries based on site feasibility assessment. Expansion Cohorts: Subjects must have measurable disease per RECIST 1.1 as determined by the Investigator. Tumor tissue material collected approximately 2 years prior to consent. If archival tumor tissue is not available, a fresh tumor biopsy may be collected from subjects enrolled in the Dose-Escalation Stage and must be collected from subjects in the Cohort-Expansion Stage, at least 7 days (and up to 60 days) prior to first dose. Recovery to baseline or ≤ Grade 1 severity (Common Terminology Criteria for Adverse Events version 5 [CTCAE v5]) from AEs. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1. Adequate organ and marrow function. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception. Female subjects of childbearing potential must not be pregnant at screening. Exclusion Criteria: Receipt of prior therapies as defined in study protocol Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. Uncontrolled, significant intercurrent or recent illness. Major surgery within 4 weeks before first dose of study treatment Corrected QT interval calculated by the Fridericia formula (QTcF) > 480 ms per electrocardiogram (ECG). Pregnant or lactating females Previously identified allergy or hypersensitivity to components of study treatment formulations or history of severe infusion-related reactions to monoclonal antibodies. Diagnosis of another malignancy within 2 years before first dose of study treatment, except for superficial non-melanoma cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Exelixis Clinical Trials
Phone
1-888-EXELIXIS (888-393-5494)
Email
druginfo@exelixis.com
First Name & Middle Initial & Last Name or Official Title & Degree
Backup or International
Phone
650-837-7400
Facility Information:
Facility Name
Exelixis Clinical Site #20
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85704
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #21
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #16
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06511
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #22
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20007
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #6
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #18
City
Columbia
State/Province
Maryland
ZIP/Postal Code
21044
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #25
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #19
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #10
City
Detroit
State/Province
Michigan
ZIP/Postal Code
49201
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #5
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #11
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68130
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #8
City
East Brunswick
State/Province
New Jersey
ZIP/Postal Code
08816
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #7
City
New Brunswick
State/Province
New Jersey
ZIP/Postal Code
08903
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #23
City
Albany
State/Province
New York
ZIP/Postal Code
12206
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #12
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #15
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #4
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #3
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #24
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #1
City
Austin
State/Province
Texas
ZIP/Postal Code
78758
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #14
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #2
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #9
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22903
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #17
City
Madrid
ZIP/Postal Code
28027
Country
Spain
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #13
City
Madrid
ZIP/Postal Code
28223
Country
Spain
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

We'll reach out to this number within 24 hrs